By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exiqon today announced it has issued a non-exclusive license to Idexx Laboratories for its LNA (locked nucleic acid) technology for veterinary disease diagnostic products.

The deal provides Exiqon with upfront and milestone payments, as well as royalty payments on global sales of products covered by the agreement. Further financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.